|
CHOZN® ZFN-modified CHO cell lines for Bioproduction
The foundation for biopharmaceutical companies to develop a platform production process, thus enabling regulatory acceptance and commercial consistency, is a robust cell line that maintains favorable growth and productivity characteristics.
SAFC® has created a series of zinc finger nuclease (ZFN) modified CHO cell lines with characteristics that are attractive in a platform cell line to biopharmaceutical developers and manufacturers. These characteristics include selecting the cells for their capacity to exhibit:
 |
Cloning robustness with low or no selection required |
|
High growth and productivity – both Qp and volumetric |
|
Suspension growth in chemically-defined media |
|
Responsiveness to feeds |
|
Scalability in bioreactors |
|
Complete traceability and safety testing |
| CHOZN ZFN-Modified CHO Cell Lines |
| Product No. |
Description |
| CHOGS |
CHOZN ZFN-Modified GS-/- CHO Cell Line |
| CHODHFR |
CHOZN ZFN-Modified DHFR-/- CHO Cell Line |
CHOZN GS-/-: First-Ever Commercially Available CHO K1 GS Knockout Cell Line
| Features |
Benefits |
| GS-/- CHO K1 |
Enables rapid development of recombinant cell lines by strong metabolic selection
GS knockout enables strong metabolic selection without the addition of MSX (GS inhibitor)
Fewer clones need to be screened to isolate robust, high-producers = decreased cell line development resources
GS selection is industry accepted method
No IP or associated royalties |
| CHOZN GS-/- cell line developed by targeted mutagenesis using the ZFN technology |
Significant decrease in the possibility for off-target mutations that result from traditional mutagenesis strategies |
| Cell line adapted to suspension growth in chemically defined, animal component free media |
Regulatory friendly
Easy to scale up |
| Cells originated from ECACC CHO K1 |
Cell maintain CHO K1 robust growth characteristics |
| cGMP manufactured, full viral testing, complete traceability |
Regulatory friendly |
Comprehensive protocols detailing recommended selection strategies
Trouble shooting with readily accessible technical experts |
Easy to use |
Additional CHOZN GS Cell Line Information and Literature for Download
CHOZN ZFN-Modified DHFR-/- CHO cell line
| Features |
Benefits |
| DHFR deficient CHO K1 parental |
Rapid metabolic selection of recombinant drug-producing cell lines
Enables further gene amplification
No IP or associated royalties |
| CHOZN DHFR-/- line developed by targeted mutagenesis with ZFNs |
Greatly reduced risk of off-target deleterious effects relative to traditional mutagenesis |
| Cell line adapted to suspension in chemically-defined and animal component free medium |
Regulatory friendly and enhanced safety
Easy to scale up |
| Derived from original ECACC CHO K1 |
Maintain favorable CHO K1 growth – lower doubling-time and reduced clumping when compared to DG44 |
| Complete trace-ability and rigorous safety testing |
Enhanced reliability and regulatory-friendly |
Additional CHOZN DHFR Cell Line Information and Literature for Download
NEW CHOZN Platform
SAFC has created the first ever commercially available cell line platform that allows for faster, simpler selection and scale up of high producing clones for the production of recombinant protein drugs. Learn more about this streamlined production solution.
|
